Refine Search

All active links listed wil take you to that organisations's website and they are responsible for keeping information up-to-date.

Displaying 21-30 of 279 result(s)

 
 

Myeloma - Osteonecrosis of the jaw (ONJ) (fact sheet)

This Fact Sheet provides information about Osteonecrosis of the jaw (ONJ) which involves the loss or breakdown of a small segment of the jaw bone. It appears to be related to long-term treatment with drugs used to treat bone disease in myeloma and other cancers, which are known as bisphosphonates, particularly in the intravenous (IV) type. This Fact Sheet includes risk factors for people, symptoms, treatment and prevention for ONJ.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Managing symptoms and side effects, Strategies to reduce cancer risk, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2012

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Unclassified MDS (fact sheet)

Unclassified MDS is a rare form of MDS. For many people, MDS can remain stable for many years,causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia. This fact sheet includes what unclassified MDS is, risks it will transform to acute myeloid leukaemia (AML), its potential causes and treatments.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Complementary / Alternative therapy, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myeloma - What is it? (fact sheet)

This fact sheet in about myeloma and how it is treated. More than 1500* Australians are expected to be diagnosed with myeloma in 2013 – equivalent to four people every day.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) - RAEB Refractory Anaemia with Excess Blasts (fact sheet)

This fact sheet provides information about Refractory Anaemia with Excess Blasts (RAEB), especially how it is treated. RAEB 1 and 2 constitutes about 40% of all MDS cases. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) – RCMD Refractory Cytopenia with Multilineage Dysplasia (fact sheet)

This fact sheet provides information about whom RCMD will affect and how it is treated. RCMD constitutes about 30% of all MDS cases. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) – RCUD Refractory Cytopenia with Unilineage Dysplasia (fact sheet)

This Fact sheet provides information on Refractory Cytopenia with Unilineage Dysplasia (RCUD) which constitutes about 10-20% of all cases of Myelodysplastic Syndrome (MDS). It includes what MDS and RCUD are, treatment and side effects. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) - RARS - Refractory Anaemia with Ring Sideroblasts (fact sheet)

This fact sheet includes what is Myelodysplastic syndrome (MDS) and Refractory Anaemia with Ring Sideroblasts (RARS), the risk RARS in transforming to acute myeloid leukaemia (AML),who will be affected and its treatment. RARS constitutes about 3-11% of all MDS cases. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Disease stages, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

About Bortezomib (Myeloma) (fact sheet)

This fact sheet provides information about Bortezomib (Velcade®). Bortezomib is the first in a new class of anti-cancer drugs. This fact sheet includes how Bortezomib works and how it is administrated.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Lenalidomide (Myeloma) (fact sheet)

This fact sheet provides information on what Lenalidomide is, its dosage and side effects. Lenalidomide is an immunomodulatory drug (IMiD). Lenalidomide, which is related to thalidomide (Thalomid®) was approved in Australia in 2007 as a treatment for multiple myeloma which has progressed on another therapy. Lenalidomide is often combined with dexamethasone in the treatment of multiple myeloma.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) - with Deletion 5q Abnormality (fact sheet)

This fact sheet provides information about the potential cause of Myelodysplastic Syndrome (MDS), its treatment and side effect. Deletion 5q is a rare form of MDS. For many people, MDS can remain stable for many years causing few symptoms. For others it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Check ups, Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Do you know of other resourceful websites? Why not let us know

Report bad content

Please enter the letters as they are shown in the image above. Letters are not case-sensitive.